A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

147

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Multiple Myeloma

Interventions

DRUG: Masitinib
DRUG: Placebo
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

AB Science